Overview

Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda